Vanessa Bolejack

TL;DR: Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.

TL;DR: The primary endpoint of overall response was not met, but pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and expansion to expanded cohorts of those subtypes is ongoing.

TL;DR: Results of this phase‐2 study demonstrated that bortezomib could be safely combined with multi‐agent chemotherapy, effecting near‐complete remission status and 2‐year survival rates in more than 80% of patients.

TL;DR: Young patients were more frequently male, had more favorable features such as low International Staging System and Durie-Salmon stage as well as less frequently adverse prognostic factors including high C-reactive protein (CRP), low hemoglobin, increased serum creatinine, and poor performance status, and seem to account for the significantly longer survival of young patients with multiple myeloma.